Author:
De La Cerda Jose,Dunshee Curtis,Gervasi Lawrence,Sieber Paul,Belkoff Laurence,Tutrone Ronald,Lu Sophia,Gatoulis Sergio C.,Brown Bruce,Migoya Elizabeth,Shore Neal
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Oncology
Reference18 articles.
1. ORGOVYX (relugolix) tablets [package insert]. Brisbane: Myovant Sciences, Inc.; 2022.
2. ORGOVYX (relugolix) tablets [summary of product characteristics]. Barcelona, Spain: Accord Healthcare S.L.U. Available at: https://www.ema.europa.eu/en/documents/product-information/orgovyx-epar-product-information_en.pdf. Accessed 26 Jan 2023.
3. Suzuki H, Uemura H, Mizokami A, et al. Phase I trial of TAK-385 in hormone treatment-naïve Japanese patients with nonmetastatic prostate cancer. Cancer Med. 2019;8(13):5891–902.
4. MacLean DB, Shi H, Faessel HM, et al. Medical castration using the investigational oral GnRH antagonist TAK-385 (relugolix): phase 1 study in healthy males. J Clin Endocrinol Metab. 2015;100:4579–87.
5. Dearnaley DP, Saltzstein DR, Sylvester JE, et al. The oral gonadotropin-releasing hormone receptor antagonist relugolix as neoadjuvant/adjuvant androgen deprivation therapy to external beam radiotherapy in patients with localised intermediate-risk prostate cancer: a randomised, open-label, parallel-group phase 2 trial. Eur Urol. 2020;78(2):184–92.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献